Obesity biotech Kailera gets $600M to start Phase 3 this yearnews2025-10-14T11:06:10+00:00October 14th, 2025|Endpoints News|
Johnson & Johnson to spin out orthopedics businessnews2025-10-14T11:01:12+00:00October 14th, 2025|Endpoints News|
Bristol Myers, insitro extend ALS drug research dealnews2025-10-14T11:00:40+00:00October 14th, 2025|Endpoints News|
Novavax’s second-largest shareholder calls for sale of vaccine makernews2025-10-14T10:49:36+00:00October 14th, 2025|Endpoints News|
Ex-Biofourmis CEO’s new startup OutcomesAI raises $10Mnews2025-10-14T10:00:47+00:00October 14th, 2025|Endpoints News|
Takeda, Nabla Bio sign second research deal for AI-made proteinsnews2025-10-14T09:00:52+00:00October 14th, 2025|Endpoints News|
Three big questions ahead of third-quarter pharma earningsnews2025-10-13T20:09:50+00:00October 13th, 2025|Endpoints News|
FDA on pace for lowest number of new drug approvals since 2022news2025-10-13T19:30:48+00:00October 13th, 2025|Endpoints News|
California enacts state law building on PBM reformsnews2025-10-13T19:24:46+00:00October 13th, 2025|Endpoints News|
FDA hands OAI classification to Novo Nordisk’s troubled Indiana sitenews2025-10-13T15:38:49+00:00October 13th, 2025|Endpoints News|
